Cadrenal Therapeutics, Inc. (CVKD)
NASDAQ: CVKD · IEX Real-Time Price · USD
0.610
-0.027 (-4.21%)
At close: Mar 28, 2024, 4:00 PM
0.640
+0.030 (4.92%)
After-hours: Mar 28, 2024, 7:43 PM EDT
Company Description
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company.
The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.
The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Cadrenal Therapeutics, Inc.
Country | United States |
Founded | 2022 |
IPO Date | Jan 20, 2023 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 4 |
CEO | Quang X. Pham |
Contact Details
Address: 822 A1a North, Suite 300 Ponte Vedra, Florida 32082 United States | |
Phone | 904-300-0701 |
Website | cadrenal.com |
Stock Details
Ticker Symbol | CVKD |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $5.00 |
CIK Code | 0001937993 |
ISIN Number | US1276361086 |
Employer ID | 88-0860746 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Douglas W. Losordo FACC, FAHA, M.D. | Chief Medical Officer |
Quang X. Pham | Chairman and Chief Executive Officer |
Matthew K. Szot CPA, CPA | Chief Financial Officer |
Jeffrey Cole | Chief Operating Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 20, 2024 | EFFECT | Notice of Effectiveness |
Mar 12, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
Mar 12, 2024 | S-3 | Registration statement under Securities Act of 1933 |
Mar 12, 2024 | 8-K | Current Report |
Mar 11, 2024 | 8-K | Current Report |
Mar 11, 2024 | 10-K | Annual Report |
Mar 5, 2024 | 8-K | Current Report |
Feb 15, 2024 | 8-K/A | [Amend] Current report |
Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |